Benjamin Bovell-Ammon to Substance Withdrawal Syndrome
This is a "connection" page, showing publications Benjamin Bovell-Ammon has written about Substance Withdrawal Syndrome.
Connection Strength
0.417
-
Hsu HE, Lodi S, Yan S, Bovell-Ammon BJ, Christine PJ, Tilhou AS, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment. JAMA Netw Open. 2026 Jul 01; 9(7):e2623280.
Score: 0.218
-
Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Aug; 120(8):1634-1645.
Score: 0.199